||This article includes a list of references, related reading or external links, but its sources remain unclear because it lacks inline citations. (March 2013)|
Herbert D. Kleber, M.D., is an American psychiatrist and substance abuse researcher. From 1968 to 1989, he founded and headed the Drug Dependence Unit at Yale University, where he was Professor of Psychiatry. He then served for 2½ years as the Deputy Director for Demand Reduction at the Office of National Drug Control Policy in the White House.
In 1992, Dr. Kleber, with his late wife, Dr. Marian Fischman, co-founded the Substance Abuse Division, one of the leading centers in the country, within the Department of Psychiatry at Columbia University. He is Director of that Division, and heads a number of projects on new methods to treat individuals with cocaine, heroin, prescription opioids, alcohol, or marijuana problems. He also co-founded the National Center on Addiction and Substance Abuse at Columbia University (CASA) with Joseph Califano.
Dr. Kleber is author or co-author of more than 250 papers, and the co-Editor of the American Psychiatric Press Textbook of Substance Abuse Treatment, now in its 4th edition. He has received numerous prestigious awards and two honorary degrees. In 2014 it was reported that he serves as a paid consultant to the opioid pharmaceutical industry.
He is listed as one of the “Best Doctors in America” and “Best Doctors in New York,” and was elected in 1996 to be a member of the Institute of Medicine of the National Academy of Science. He is on the Board of a number of organizations, including the Partnership for a Drug Free America, the Treatment Research Institute at the University of Pennsylvania, and the Betty Ford Institute.
- Department of Psychiatry, Columbia University College of Physicians and Surgeons
- New York State Psychiatric Institute
- Faculty Profile for Herbert D. Kleber, M.D.
- Consulting activities 
- Fang, Lee (August 27, 2014). Leading Anti-Marijuana Academics Are Paid by Painkiller Drug Companies. Vice. Retrieved November 22, 2014.